SRU Biosystems Installs its BIND® Reader For Label-free Drug Profiling using Primary Cells at GlaxoSmithKline

Business Wire, March 20, 2008

WOBURN, Mass. -- SRU Biosystems, Inc., a leader in highly sensitive labeled and label-free detection technologies, today announced that GlaxoSmithKline purchased the BIND([R]) Reader system at its drug discovery site in Harlow, UK. The sale marks an important validation of the BIND([R]) system for cell based assays.

"SRU has focused its efforts to enable the use of cell based assays on its instrument platform with the goal of having a versatile product portfolio that spans assay development through high throughput screening," said Richard Wagner, President and CEO of SRU Biosystems. "The technology is uniquely suited for studying endogenous receptors in native and primary cells, a current unmet need in the drug discovery industry. We have had an excellent, long-standing relationship with GSK that has allowed us together to exploit this exciting new application."

The Company has developed its BIND([R]) product line for cell based applications, small molecule/fragment screening, and antibody screening. The BIND([R]) system includes the BIND([R]) Reader, advanced user-friendly software tools, and 96-, 384-, or 1536-well microplates with proprietary coatings for attaching cells or proteins. The BIND([R]) Reader uses the Company's patented optical biosensor technology and is easily integrated into a semi-automated or fully automated environment for kinetic or endpoint assays in an HTS mode. Please see the Company's website for upcoming product demonstrations and tutorials.

About SRU Biosystems

SRU Biosystems, Inc., is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical and cellular targets. SRU is incorporating its technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics. www.srubiosystems.com